Teva’s New CEO Francis: No Revolution, But New Strategy Will Not Be Marginal
Newly Appointed Company Head Speaks For First Time At J.P. Morgan Conference
Executive Summary
On the final day of the annual J.P. Morgan Healthcare Conference, Richard Francis, with vast experience at Biogen and Sandoz under his belt, faced investors for the first time as Teva’s CEO, after replacing Kåre Schultz on 1 January.
You may also be interested in...
Teva Eyes ‘80% Of Off-Patent Opportunities’ For Generics And Biosimilars
Teva’s president and CEO Kåre Schultz provided fresh long-term financial targets for the company in the wake of the firm agreeing in principle to settle opioid-related claims in the US – but will the architect of Teva’s restructuring remain beyond his current November 2023 contract?
Krka Talks Russia, Ukraine, One Year After Conflict Began
Slovenia’s Krka enjoyed a solid year for its dominant Prescription Pharmaceuticals business, with sales climbing by 7% on the back of growth for all six of its geographic business units.
Vascepa Infringement Dismissal ‘Resulted In Multiple Errors,’ Amarin Argues
Amarin is digging deep to take Hikma back before a US district court in its induced infringement case against the generics manufacturer.